Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

AIDS

Volumn 17, Issue 10, 2003, Pages 1568-1570

  Baldanti, Fausto ^a   Paolucci, Stefania ^a   Maga, Giovanni ^b   Labo, Nazzarena ^a   Hübscher, Ulrich ^c   Skoblov, Alexander Yu ^d   Victorova, Lyubov ^d   Spadari, Silvio ^b   Minoli, Lorenzo ^e   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; CROSS RESISTANCE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS RECOMBINANT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TREATMENT FAILURE;

EID: 0041366954     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200307040-00021     Document Type: Article

References (6)

1. Maga G, Spadari S. Combinations against combinations: associations of anti-HIV 1 reverse transcrlptase drugs challenged by constellations of drug resistance mutations. Curr Drug Metab 2002; 3:73-95.
2. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999; 43:1961-1967.
3. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994; 38:1428-1432.
4. Shih C-K, Rose JM, Hansen GL, Wu JC, Bacolla A, Griffin JA. Chimeric human immunodeficiency virus type1/type2 reverse transcriptase display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A 1991; 88:9878-9882.
5. Boucher C, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996; 40:2404-2409.
6. Maga G, Amacker M, Ruel N, Hübscher U, Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol 1997; 274:738-747.